These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12904741)

  • 1. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
    ;
    MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(31):735-9. PubMed ID: 12904741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 6. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
    Ijaz K; Jereb JA; Lambert LA; Bower WA; Spradling PR; McElroy PD; Iademarco MF; Navin TR; Castro KG
    Clin Infect Dis; 2006 Feb; 42(3):346-55. PubMed ID: 16392079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

  • 9. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
    Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
    Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
    Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
    Cook PP; Maldonado RA; Yarnell CT; Holbert D
    Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
    Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection.
    Castro KG; Jereb JA; Koppaka VR; Cohn DL
    Chest; 2003 Mar; 123(3):967. PubMed ID: 12628913
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
    Sterling TR; Njie G; Zenner D; Cohn DL; Reves R; Ahmed A; Menzies D; Horsburgh CR; Crane CM; Burgos M; LoBue P; Winston CA; Belknap R
    MMWR Recomm Rep; 2020 Feb; 69(1):1-11. PubMed ID: 32053584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.